TITLE
Neoadjuvant anastrozole alone or with gefitinib in early breast cancer

ORGANISM
Homo sapiens

SUMMARY
Trial 223 was a placebo-controlled trial of neoadjuvant anastrozole  alone or with gefitinib in early breast cancer. We used patients from  arm B and C: anastrozole 1mg/d for the duration of the 16 week period  plus placebo 1 tablet/d orally for 2 weeks. Patients in arm B were  followed by gefitinib 250mg/d orally for 14 weeks whereas patients in  arm C continued with placebo for 14 weeks.

DESIGN
96 samples

PLATFORM
GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array

CITATIONS
Has this study been published? Please login to update or notify GEO .

